
Zhejiang Taimei Medical Technology Co., Ltd.
2576.HKHKSETechnologySoftware - Application
Latest quote
HK$5.395
−HK$0.15 · -2.71%
2576.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteZhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.
- Industry
- Software - Application
- Sector
- Technology
- Headquarters
- CN
- CEO
- Wan Yunyun
- Listed since
- Oct 8, 2024
- Employees
- 681
Market position
Day range
Current HK$5.395
52-week range
Current HK$5.395
- Open
- HK$5.60
- Previous close
- HK$5.545
- Volume
- 280.4K
- 0.35× average
- Average volume
- 812.4K
- Average daily volume
- Market cap
- 3.04B HKD
- Beta
- 0.01
- Market reference 1
- 50-day average
- HK$5.8397
- -7.62% below average
- 200-day average
- HK$4.7971
- +12.46% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.44B CNY
- P/E (TTM)
- -129.9×
- P/B (TTM)
- 2.32×
- P/S (TTM)
- 9.72×
- EV / EBITDA
- -49.5×
- Earnings yield
- -2.08%
- Free cash flow yield
- -2.15%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 43.74%
- Operating margin
- -13.72%
- Net margin
- -7.47%
- Return on equity
- -3.72%
- Return on assets
- -2.68%
- Return on invested capital
- -4.78%
Financial health
- Debt / equity
- 0.05×
- Current ratio
- 4.47×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 499.28M CNY | 551.16M CNY | 573.14M CNY | 549.22M CNY | 466.18M CNY |
| Cost of goods sold | 287.37M CNY | 326.21M CNY | 394.14M CNY | 363.81M CNY | 301.85M CNY |
| Gross profit | 211.91M CNY | 224.94M CNY | 179M CNY | 185.4M CNY | 163.59M CNY |
| Research and development | 76.63M CNY | 87.05M CNY | 169.19M CNY | 233.69M CNY | 225.09M CNY |
| Selling, general, and administrative | 196.78M CNY | 382.02M CNY | 384.89M CNY | 48.99M CNY | 46.22M CNY |
| Operating expenses | 273.41M CNY | 477.4M CNY | 575.59M CNY | 628.19M CNY | 669.97M CNY |
| Interest income | 34.72M CNY | 35.77M CNY | 41.65M CNY | 22.88M CNY | 28.74M CNY |
| Interest expense | 811.44K CNY | 727K CNY | 1.43M CNY | 2.68M CNY | 2.71M CNY |
| Depreciation and amortization | 19.46M CNY | 39.95M CNY | 51.96M CNY | 55.53M CNY | 36.51M CNY |
| Operating income | −61.5M CNY | −252.45M CNY | −396.59M CNY | −442.78M CNY | −505.63M CNY |
| Net income | −41.74M CNY | −214.61M CNY | −346.78M CNY | −412.91M CNY | −479.61M CNY |
Company facts updated Aug 24, 2026.
2576.HK peers
Continue in GoAI
Research 2576.HKresearch.disclaimer





